vigabatrin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
gabamimetic agents	2819	68506-86-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vigabatrin (+/-)-4-Amino-5-hexenoic acid sabril vigabatrin hydrochloride vigabatrin HCl	The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system. Molecular weight: 129.16 Formula: C6H11NO2 CLOGP: -2.22 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: -0.13 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vigabatrin
(+/-)-4-Amino-5-hexenoic acid
sabril
vigabatrin hydrochloride
vigabatrin HCl

The precise mechanism of vigabatrin's anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system.

Molecular weight: 129.16
Formula: C6H11NO2
CLOGP: -2.22
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 63.32
ALOGS: -0.13
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	442.42 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 21, 2009	FDA	LUNDBECK LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1749.00	32.41	613	6050	132021	63350338
Drug withdrawal convulsions	670.35	32.41	118	6545	1307	63481052
Product dose omission issue	282.93	32.41	217	6446	234096	63248263
Retinogram abnormal	276.24	32.41	41	6622	130	63482229
Magnetic resonance imaging head abnormal	273.77	32.41	59	6604	1954	63480405
Status epilepticus	270.91	32.41	89	6574	15144	63467215
Death	233.01	32.41	238	6425	374143	63108216
Drug ineffective	214.07	32.41	385	6278	1044380	62437979
Irritability	159.27	32.41	74	6589	31620	63450739
Drug resistance	158.59	32.41	67	6596	22866	63459493

Showing 1 to 10 of 50 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1614.09	39.36	637	6063	104220	34846011
Drug withdrawal convulsions	590.64	39.36	113	6587	1064	34949167
Product dose omission issue	335.72	39.36	234	6466	119477	34830754
Drug ineffective	262.94	39.36	374	6326	456377	34493854
Magnetic resonance imaging head abnormal	245.17	39.36	56	6644	1305	34948926
Status epilepticus	242.16	39.36	91	6609	12523	34937708
Visual field defect	213.04	39.36	64	6636	4419	34945812
Retinogram abnormal	210.77	39.36	34	6666	99	34950132
Death	122.90	39.36	248	6452	397801	34552430
Multiple-drug resistance	115.94	39.36	42	6658	5197	34945034

Showing 1 to 10 of 44 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	1902.79	31.52	741	8711	188093	79546843
Drug withdrawal convulsions	777.92	31.52	146	9306	2074	79732862
Retinogram abnormal	457.31	31.52	71	9381	282	79734654
Product dose omission issue	456.81	31.52	311	9141	247226	79487710
Status epilepticus	442.53	31.52	150	9302	24891	79710045
Death	349.30	31.52	379	9073	566135	79168801
Magnetic resonance imaging head abnormal	259.20	31.52	61	9391	2665	79732271
Visual field defect	219.67	31.52	69	9383	8976	79725960
Drug ineffective	210.18	31.52	419	9033	1080494	78654442
Drug resistance	190.09	31.52	95	9357	42118	79692818

Showing 1 to 10 of 68 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N03AG04	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Fatty acid derivatives
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:63674	4-aminobutyrate transaminase inhibitors
FDA EPC	N0000175753	Anti-epileptic Agent
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018682	GABA Agents
MeSH PA	D018377	Neurotransmitter Agents

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
West syndrome	indication	28055006
Epilepsy characterized by intractable complex partial seizures	indication	442481002
Suicidal thoughts	contraindication	6471006
Weight gain finding	contraindication	8943002
Visual field defect	contraindication	12184005
Reduced visual acuity	contraindication	13164000
Mood swings	contraindication	18963009
Kidney disease	contraindication	90708001	DOID:557
Edema	contraindication	267038008
Anemia	contraindication	271737000	DOID:2355

Showing 1 to 10 of 13 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.94	acidic
pKa2	10.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
4-aminobutyrate aminotransferase, mitochondrial	Enzyme	P80404	GABT_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Gamma-amino-N-butyrate transaminase	Enzyme		GABT_RAT		IC50	4.38	CHEMBL
4-aminobutyrate aminotransferase, mitochondrial	Enzyme		GABT_MOUSE		IC50	4.40	CHEMBL

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
003774	NDDF
14851	RXNORM
15507	MMSL
310283001	SNOMEDCT_US
322976008	SNOMEDCT_US
36115	MMSL
4025280	VUID
4025280	VANDF
4821	IUPHAR_LIGAND_ID
52922	MMSL

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-111	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-111	TABLET, FILM COATED	500 mg	ORAL	NDA	31 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-211	POWDER, FOR SOLUTION	50 mg	ORAL	NDA	32 sections
SABRIL	HUMAN PRESCRIPTION DRUG LABEL	1	67386-211	POWDER, FOR SOLUTION	50 mg	ORAL	NDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0652	TABLET	500 mg	ORAL	ANDA	33 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0201	TABLET	500 mg	ORAL	ANDA	31 sections
VIGABATRIN	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0470	POWDER, FOR SOLUTION	500 mg	ORAL	ANDA	32 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3851	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3851	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
vigabatrin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3955	POWDER, FOR SOLUTION	50 mg	ORAL	ANDA	30 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next